300401 Zhejiang Garden Biopharmaceutical
- 11.83
- +0.52+4.60%
Zhejiang Garden Biopharmaceutical News
Individual Investors Among Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 6.6% Last Week
Key Insights The considerable ownership by individual investors in Zhejiang Garden BiopharmaceuticalLtd indicates that they collectively have a greater say in management and business strategy The to
Garden Biology (300401.SZ): In the future, we will unswervingly promote the dual layout of “chemical synthesis and biosynthesis”
Gelonghui, May 9, 丨 Garden Biology (300401.SZ) said on the investor interactive platform that the company's existing products mainly use chemical synthesis. In the future, the company will unswervingly promote the dual layout of “chemical synthesis and biosynthesis”. Currently, it has invested abroad to establish a joint venture “Zhejiang Garden Biotechnology Co., Ltd.” to increase the company's market and technology development efforts in the field of amino acid and vitamin biosynthesis. At the same time, the company plans to invest in the construction of a “pilot base project with an annual output of 10,000 tons of L-alanine (fermentation method) and biological manufacturing”, which uses advanced biological manufacturing methods.
Garden Biotech (300401.SZ) 2023 equity distribution: $0.71 for every 10 shares, shares registered on May 14
According to the Zhitong Finance App, Huayuan Biotech (300401.SZ) announced that the company's 2023 equity distribution plan is to distribute a cash dividend of 0.71 yuan to all shareholders for every 10 shares based on the total share capital on the registration date of the company's equity distribution. The share registration date for this equity distribution is: May 14, 2024, and the excluding dividend date is: May 15, 2024.
Earnings Not Telling The Story For Zhejiang Garden Biopharmaceutical Co.,Ltd. (SZSE:300401) After Shares Rise 27%
Despite an already strong run, Zhejiang Garden Biopharmaceutical Co.,Ltd. (SZSE:300401) shares have been powering on, with a gain of 27% in the last thirty days. Notwithstanding the latest gain, th
Zhejiang Garden BiopharmaceuticalLtd's (SZSE:300401) Shareholders Have More To Worry About Than Only Soft Earnings
Despite Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) recent earnings report having lackluster headline numbers, the market responded positively. While shareholders may be willing to ove
Garden Biology (300401.SZ): Net profit for 2023 fell 49.87% to 192 million yuan, and plans to distribute 10 to 0.71 yuan
On April 15, Ge Longhui (300401.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 1,095 million yuan, a year-on-year decrease of 22.78%; net profit attributable to shareholders of listed companies was 192 million yuan, a year-on-year decrease of 49.87%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 148 million yuan, a year-on-year decrease of 57.65%; basic income per share was 0.35 yuan; it plans to distribute a cash dividend of 0.71 yuan (tax included) to all shareholders for every 10 shares.
The Five-year Loss for Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) Shareholders Likely Driven by Its Shrinking Earnings
The main aim of stock picking is to find the market-beating stocks. But even the best stock picker will only win with some selections. So we wouldn't blame long term Zhejiang Garden Biopharmaceutica
Huayuan Biotech (300401.SZ) Performance Report: 2023 net profit of 192 million yuan decreased by 49.96% year-on-year
Gelonghui March 20 丨 Garden Biotech (300401.SZ) announced its 2023 annual results report. During the reporting period, the company achieved total operating revenue of 1,095 million yuan, a decrease of 22.78% over the same period of the previous year; achieved operating profit of 207 million yuan, a decrease of 52.61% over the same period of the previous year; realized total profit of 211 million yuan, a decrease of 52.39% over the same period of the previous year; and realized net profit attributable to shareholders of listed companies of 192 million yuan, a decrease of 49.96% over the same period last year. At the end of the reporting period, the company's total assets were 526,01864 million yuan, an increase of 27.31% over the beginning of the period; ownership
Garden Biology (300401.SZ): The total cost of the repurchase was about 100 million yuan to repurchase 1.69% of the shares
Gelonghui, March 7, 丨 Garden Biotech (300401.SZ) announced that as of March 6, 2024, the number of shares repurchased by the company through centralized bidding transactions was 9,307,200 shares, accounting for 1.69% of the company's current total share capital. The minimum transaction price was 10.09 yuan/share, the highest transaction price was 11.83 yuan/share, and the total transaction amount was about RMB 100 million (including transaction fees). The company has completed this repurchase. The actual repurchase period is from September 14, 2023 to March 6, 2024.
Garden Biology (300401.SZ): 1.69% of shares have been repurchased cumulatively
Gelonghui, March 4, 丨 Garden Biotech (300401.SZ) announced that as of February 29, 2024, the number of shares repurchased by the company through centralized bidding transactions was 9,307,200 shares, accounting for 1.69% of the company's current total share capital. The minimum transaction price was 10.09 yuan/share, the highest transaction price was 11.83 yuan/share, and the total transaction amount was RMB 100 million (including transaction fees).
Garden Biology (300401.SZ): Amlodipine atorvastatin calcium tablets obtained drug registration certificate
Gelonghui (300401.SZ) announced on March 1, that Zhejiang Huayuan Pharmaceutical Co., Ltd. (“Huayuan Pharmaceutical”), a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for “amlodipine atorvastatin calcium tablets” approved and issued by the State Drug Administration. Amlodipine atorvastatin calcium tablets are mainly used to treat high blood pressure and angina pectoris in adults with high blood lipids. They are suitable for patients treated with amlodipine and atorvastatin. According to data from the Mi Intranet, the market size of amlodipine atorvastatin calcium tablets in public medical institutions in 2022 was 913 million yuan.
Zhejiang Garden Biopharmaceutical's Unit Gets Nod for Eight New Products
Zhejiang Garden Biopharmaceutical's (SHE:300401) unit, Zhejiang Garden Nutrition Technology, obtained approval for eight of its new feed additive products. The products are feed additives with vitamin
Garden Biology (300401.SZ): A total cost of 999.543 million yuan to buy back 1.69% of the shares
Gelonghui, February 2, 丨 Garden Biotech (300401.SZ) announced that as of January 31, 2024, the number of shares repurchased by the company through centralized bidding transactions through a special stock repurchase account was 9.3072 million shares, accounting for 1.69% of the company's current total share capital. The minimum transaction price was 10.09 yuan/share, the maximum transaction price was 11.83 yuan/share, and the total transaction amount was RMB 99,543 million (excluding transaction fees).
Garden Biology (300401.SZ): Plans to invest in the establishment of a joint venture in Jinhua City, Zhejiang Province
Gelonghui February 1 丨 Garden Biology (300401.SZ) announced that the company and Liu Zhiqiang signed a “Joint Venture Agreement” to invest in the establishment of a joint venture “Zhejiang Garden Biotechnology Co., Ltd.” in Jinhua City, Zhejiang Province. The registered capital of the joint venture is RMB 20 million, Huayuan Biotech invested 90%, and Liu Zhiqiang invested 10%.
These 4 Measures Indicate That Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) Is Using Debt Extensively
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usu
Garden Biology (300401.SZ): 2023 net profit pre-reduced by 42.67%-53.09%
On January 12, Ge Longhui (300401.SZ) announced its 2023 annual results forecast. Net profit attributable to shareholders of listed companies during the reporting period was 180 million yuan to 220 million yuan, down 53.09%-42.67% from the same period last year; net profit profit after deducting non-recurring profit and loss was 133 million yuan to 173 million yuan, down 61.84%-50.37% from the same period last year. During the reporting period, it was mainly affected by the year-on-year decline in sales prices of pharmaceutical products and vitamin D3 products. The current period's operating income and product gross margin declined year-on-year. During the reporting period
Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Shares May Have Run Too Fast Too Soon
It's not a stretch to say that Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) price-to-earnings (or "P/E") ratio of 33.8x right now seems quite "middle-of-the-road" compared to the market
Garden Biology (300401.SZ): A total cost of 86.6921 million yuan to buy back 1.47% of the shares
Gelonghui, January 3, 丨 Garden Biotech (300401.SZ) announced that as of December 31, 2023, the number of shares repurchased by the company through centralized bidding transactions was 8.1181 million shares, accounting for 1.47% of the company's current total share capital. The minimum transaction price was 10.09 yuan/share, the highest transaction price was 11.83 yuan/share, and the total transaction amount was RMB 86.6921 million (excluding transaction fees).
Huayuan Biotech (300401.SZ) obtained a drug registration certificate for “dobaserazide tablets”
Huayuan Biotech (300401.SZ) announced that Zhejiang Huayuan Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received China...
Investors Who Have Held Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) Over the Last Year Have Watched Its Earnings Decline Along With Their Investment
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if you buy individual stocks, you can do both better or worse than that. Unfortunate
Analysis
Price Target
No Data
